This model is of the protease protein from human immunodeficiency virus
(HIV). Olson directs a large National Institutes of Health grant that
seeks to establish a drug design cycle aimed at developing, testing,
and refining novel approaches to making specific inhibitors of HIV protease
that are capable of limiting or eliminating drug resistance.
